[1]Han SJ,Zhang SW,Chen WQ,et al.An analysis of the status and trends of prostate cancer in China[J].J Clin Oncol,2013,18(4):330-334.[韩苏军,张思维,陈万青,等.中国前列腺癌发病现状和流行趋势分析[J].临床肿瘤学杂志,2013,18(4):330-334.]
[2]Cullen J,Elsamanoudi S,Brassell SA,et al.The burden of prostate cancer in Asian nations[J].J Carcinog,2012,11:7.
[3]Ye DW,Gu CY,Zhu Y.The main points of interpretation and analysis of NCCN prostate cancer Asian consensus clinical practice guidelines (V2.2013 version)[J].Chin J Surg,2015,53(1):63-67.[叶定伟,顾成元,朱耀.NCCN前列腺癌临床实践指南亚洲共识(V2.2013版)要点解读与分析[J].中华外科杂志,2015,53(1):63-67.]
[4]Verma S,Rajesh A,Morales H,et al.Assessment of aggressiveness of prostate cancer:Correlation of apparent diffusion coefficient with histologic grade after radical prostatectomy[J].AJR Am J Roentgenol,2011,196(2):374-381.
[5]Ren S,Wang F,Shen J,et al.Long non-coding RNA metastasis associated in lung adenocarcinoma transcript 1 derived miniRNA as a novel plasma-based biomarker for diagnosing prostate cancer[J].Eur J Cancer,2013,49(13):2949-2959.
[6]Zeng YW,Lu GY,Gao WY,et al.Expression and clinical significance of Caveolin-1,p63 and CK34βE12 in 59 prostate cancer[J].Chongqing Medical Journal,2013,42(14):1589-1592.[曾永威,卢桂尧,高婉仪,等.Caveolin-1、p63及CK34βE12在59例前列腺癌中的表达及意义[J].重庆医学,2013,42(14):1589-1592.]
[7]Na Yanqun,Ye Zhangqun,Sun Yinghao,et al.China urology disease diagnosis and treatment guidelines (2014 edition)[M].Beijing:People's Health Publishing House,2014:80-81.[那彦群,叶章群,孙颖浩,等.中国泌尿外科疾病诊断治疗指南(2014版)[M].北京:人民卫生出版社,2014:80-81.]
[8]Kazemi-Shirazi L,Veloso MP,Frommlet F,et al.Differentiation of nonalcoholic from alcoholic steatohepatitis:Are routine laboratory markers useful[J].Wien Klin Wochenschr,2008,120(1-2):25-30.
[9]Zhang CY,Fang ZQ,Liang C,et al.The research progress of Cytokeratin 18 in the role of liver cancer[J].Liaoning Journal of Traditional Chinese Medicine,2012,39(3):567-570.[张翠英,方肇勤,梁超,等.细胞角蛋白18 及其在肝癌中作用的研究进展[J].辽宁中医杂志,2012,39(3):567-570.]
[10]Wang WD,Ming Z,Li YJ,et al.Expressions and clinical significance of CD147 and CK19 in hepatocellular carcinoma[J].Chinese-German Journal of Clinical Oncology,2012,11(9):517-521.
[11]Pei F,Zhu Y.The clinical significance of the detection of Cytokeratin 18 in the diagnosis of gastric cancer[J].Cancer Prevention Research,2012,39(4):439-441.[裴锋,朱毅.细胞角蛋白18片段检测在胃癌诊断中的临床意义[J].肿瘤防治研究,2012,39(4):439-441.]
[12]Huang JF,Wang JZ,Li WX,et al.The Expression and clinical significance of CK19 and Galectin-3 in the differential diagnosis of thyroid benign and malignant lesions[J].Chinese Journal of Medicinal Guide,2013,15(6):1050-1051.[黄金凤,王见璋,李炜霞,等.CK19和Galectin-3在甲状腺良恶性病变中的表达及鉴别诊断意义[J].中国医药导刊,2013,15(6):1050-1051.]
[13]Liu JT,Zhang CL,Guo HX,et al.The expression and clinical significance of CK19 and CDK4 in bladder transitional cell carcinoma[J].Acta Academiae Medicinae Weifang,2009,31(4):274-276.[刘杰田,张翠丽,郭海祥,等.CK19,CDK4在膀胱移行细胞癌中的表达及临床意义[J].潍坊医学院学报,2009,31(4):274-276.]
[14]Wang Qian,Liu Jie,Zhang Peijun,et al.Expression of CK19 mRNA and CEA mRNA of the peripheral blood of patients with colorectal carcinoma and its clinical significance[J].Modern Oncology,2015,23(08):1099-1102.[王前,刘洁,张培军,等.大肠癌患者外周血中细胞角蛋白19和癌胚抗原的表达及临床意义[J].现代肿瘤医学,2015,23(08):1099-1102.]
[15]Ute Woelfle,Guido Sauter,Sonja Santjer,et al.Down-regulated expression of cytokeratin 18 promotes progression of human breast cancer[J].Clin Cancer Res,2004,10:2670-2674.
[16]Jiang L,Li JG,Lan L,et al.Human hepatoma HepaRG cell line engraftment in severe combined immunodeficient×beige mice using mouse-specific anti-Fas antibody[J].Transplant Proc,2010,42(9):3773-3778.